Literature DB >> 33750975

DNA vaccine candidate encoding SARS-CoV-2 spike proteins elicited potent humoral and Th1 cell-mediated immune responses in mice.

Eakachai Prompetchara1,2,3, Chutitorn Ketloy1,2,3, Kittipan Tharakhet1,2, Papatsara Kaewpang1, Supranee Buranapraditkun1,4, Teerasit Techawiwattanaboon1,5, Suwitra Sathean-Anan-Kun1,5, Patrawadee Pitakpolrat1,2, Supaporn Watcharaplueksadee6, Supaporn Phumiamorn7, Wassana Wijagkanalan8, Kanitha Patarakul1,3,5, Tanapat Palaga3,9, Kiat Ruxrungtham1,3.   

Abstract

More than 65 million people have been confirmed infection with SARS-CoV-2 and more than 1 million have died from COVID-19 and this pandemic remains critical worldwide. Effective vaccines are one of the most important strategies to limit the pandemic. Here, we report a construction strategy of DNA vaccine candidates expressing full length wild type SARS-CoV-2 spike (S) protein, S1 or S2 region and their immunogenicity in mice. All DNA vaccine constructs of pCMVkan-S, -S1 and -S2 induced high levels of specific binding IgG that showed a balance of IgG1/IgG2a response. However, only the sera from mice vaccinated with pCMKkan-S or -S1 DNA vaccines could inhibit viral RBD and ACE2 interaction. The highest neutralizing antibody (NAb) titer was found in pCMVkan-S group, followed by -S1, while -S2 showed the lowest PRNT50 titers. The geometric mean titers (GMTs) were 2,551, 1,005 and 291 for pCMVkan-S, -S1 and -S2, respectively. pCMVkan-S construct vaccine also induced the highest magnitude and breadth of T cells response. Analysis of IFN-γ positive cells after stimulation with SARS-CoV-2 spike peptide pools were 2,991, 1,376 and 1,885 SFC/106 splenocytes for pCMVkan-S, -S1 and -S2, respectively. Our findings highlighted that full-length S antigen is more potent than the truncated spike (S1 or S2) in inducing of neutralizing antibody and robust T cell responses.

Entities:  

Year:  2021        PMID: 33750975      PMCID: PMC7984610          DOI: 10.1371/journal.pone.0248007

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  52 in total

1.  A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge.

Authors:  Meagan Bolles; Damon Deming; Kristin Long; Sudhakar Agnihothram; Alan Whitmore; Martin Ferris; William Funkhouser; Lisa Gralinski; Allison Totura; Mark Heise; Ralph S Baric
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

2.  DNA vaccines expressing different forms of simian immunodeficiency virus antigens decrease viremia upon SIVmac251 challenge.

Authors:  Margherita Rosati; Agneta von Gegerfelt; Patricia Roth; Candido Alicea; Antonio Valentin; Marjorie Robert-Guroff; David Venzon; David C Montefiori; Phil Markham; Barbara K Felber; George N Pavlakis
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

3.  T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice.

Authors:  Jincun Zhao; Jingxian Zhao; Stanley Perlman
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

4.  DNA vaccine protection against SARS-CoV-2 in rhesus macaques.

Authors:  Jingyou Yu; Lisa H Tostanoski; Lauren Peter; Noe B Mercado; Katherine McMahan; Shant H Mahrokhian; Joseph P Nkolola; Jinyan Liu; Zhenfeng Li; Abishek Chandrashekar; David R Martinez; Carolin Loos; Caroline Atyeo; Stephanie Fischinger; John S Burke; Matthew D Slein; Yuezhou Chen; Adam Zuiani; Felipe J N Lelis; Meghan Travers; Shaghayegh Habibi; Laurent Pessaint; Alex Van Ry; Kelvin Blade; Renita Brown; Anthony Cook; Brad Finneyfrock; Alan Dodson; Elyse Teow; Jason Velasco; Roland Zahn; Frank Wegmann; Esther A Bondzie; Gabriel Dagotto; Makda S Gebre; Xuan He; Catherine Jacob-Dolan; Marinela Kirilova; Nicole Kordana; Zijin Lin; Lori F Maxfield; Felix Nampanya; Ramya Nityanandam; John D Ventura; Huahua Wan; Yongfei Cai; Bing Chen; Aaron G Schmidt; Duane R Wesemann; Ralph S Baric; Galit Alter; Hanne Andersen; Mark G Lewis; Dan H Barouch
Journal:  Science       Date:  2020-05-20       Impact factor: 47.728

5.  Identification of immunodominant linear epitopes from SARS-CoV-2 patient plasma.

Authors:  Lluc Farrera-Soler; Jean-Pierre Daguer; Sofia Barluenga; Oscar Vadas; Patrick Cohen; Sabrina Pagano; Sabine Yerly; Laurent Kaiser; Nicolas Vuilleumier; Nicolas Winssinger
Journal:  PLoS One       Date:  2020-09-09       Impact factor: 3.240

6.  Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus.

Authors:  Ming Shum Yip; Nancy Hiu Lan Leung; Chung Yan Cheung; Ping Hung Li; Horace Hok Yeung Lee; Marc Daëron; Joseph Sriyal Malik Peiris; Roberto Bruzzone; Martial Jaume
Journal:  Virol J       Date:  2014-05-06       Impact factor: 4.099

7.  Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients.

Authors:  Yang Li; Dan-Yun Lai; Hai-Nan Zhang; He-Wei Jiang; Xiaolong Tian; Ming-Liang Ma; Huan Qi; Qing-Feng Meng; Shu-Juan Guo; Yanling Wu; Wei Wang; Xiao Yang; Da-Wei Shi; Jun-Biao Dai; Tianlei Ying; Jie Zhou; Sheng-Ce Tao
Journal:  Cell Mol Immunol       Date:  2020-09-07       Impact factor: 11.530

8.  SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.

Authors:  Kizzmekia S Corbett; Darin K Edwards; Sarah R Leist; Olubukola M Abiona; Seyhan Boyoglu-Barnum; Rebecca A Gillespie; Sunny Himansu; Alexandra Schäfer; Cynthia T Ziwawo; Anthony T DiPiazza; Kenneth H Dinnon; Sayda M Elbashir; Christine A Shaw; Angela Woods; Ethan J Fritch; David R Martinez; Kevin W Bock; Mahnaz Minai; Bianca M Nagata; Geoffrey B Hutchinson; Kai Wu; Carole Henry; Kapil Bahl; Dario Garcia-Dominguez; LingZhi Ma; Isabella Renzi; Wing-Pui Kong; Stephen D Schmidt; Lingshu Wang; Yi Zhang; Emily Phung; Lauren A Chang; Rebecca J Loomis; Nedim Emil Altaras; Elisabeth Narayanan; Mihir Metkar; Vlad Presnyak; Cuiping Liu; Mark K Louder; Wei Shi; Kwanyee Leung; Eun Sung Yang; Ande West; Kendra L Gully; Laura J Stevens; Nianshuang Wang; Daniel Wrapp; Nicole A Doria-Rose; Guillaume Stewart-Jones; Hamilton Bennett; Gabriela S Alvarado; Martha C Nason; Tracy J Ruckwardt; Jason S McLellan; Mark R Denison; James D Chappell; Ian N Moore; Kaitlyn M Morabito; John R Mascola; Ralph S Baric; Andrea Carfi; Barney S Graham
Journal:  Nature       Date:  2020-08-05       Impact factor: 49.962

9.  Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate.

Authors:  Sandhya Bangaru; Gabriel Ozorowski; Hannah L Turner; Aleksandar Antanasijevic; Deli Huang; Xiaoning Wang; Jonathan L Torres; Jolene K Diedrich; Jing-Hui Tian; Alyse D Portnoff; Nita Patel; Michael J Massare; John R Yates; David Nemazee; James C Paulson; Greg Glenn; Gale Smith; Andrew B Ward
Journal:  Science       Date:  2020-10-20       Impact factor: 47.728

10.  SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen.

Authors:  Yunfei Wang; Lichun Wang; Han Cao; Cunbao Liu
Journal:  J Med Virol       Date:  2020-10-05       Impact factor: 20.693

View more
  8 in total

1.  Immunological investigation of a multiepitope peptide vaccine candidate based on main proteins of SARS-CoV-2 pathogen.

Authors:  Niloofar Khairkhah; Azam Bolhassani; Elnaz Agi; Ali Namvar; Arash Nikyar
Journal:  PLoS One       Date:  2022-06-09       Impact factor: 3.752

Review 2.  A Review of Different Vaccines and Strategies to Combat COVID-19.

Authors:  Srinivasan Sabitha; Nagarajan Shobana; Pandurangan Prakash; Sathiyamoorthy Padmanaban; Mahendran Sathiyashree; Subramanian Saigeetha; Srikumar Chakravarthi; Saji Uthaman; In-Kyu Park; Antony V Samrot
Journal:  Vaccines (Basel)       Date:  2022-05-09

3.  DNA Based Vaccine Expressing SARS-CoV-2 Spike-CD40L Fusion Protein Confers Protection Against Challenge in a Syrian Hamster Model.

Authors:  Levi A Tamming; Diana Duque; Anh Tran; Wanyue Zhang; Annabelle Pfeifle; Emmanuel Laryea; Jianguo Wu; Sathya N Thulasi Raman; Caroline Gravel; Marsha S Russell; Anwar M Hashem; Reem M Alsulaiman; Rowa Y Alhabbab; Jun Gao; David Safronetz; Jingxin Cao; Lisheng Wang; Wangxue Chen; Michael J W Johnston; Simon Sauve; Michael Rosu-Myles; Xuguang Li
Journal:  Front Immunol       Date:  2022-01-12       Impact factor: 7.561

Review 4.  A contemporary review on the important role of in silico approaches for managing different aspects of COVID-19 crisis.

Authors:  Mohammad Moradi; Reza Golmohammadi; Ali Najafi; Mehrdad Moosazadeh Moghaddam; Mahdi Fasihi-Ramandi; Reza Mirnejad
Journal:  Inform Med Unlocked       Date:  2022-01-21

Review 5.  Possibility of exosome‑based coronavirus disease 2019 vaccine (Review).

Authors:  Kwang Ho Yoo; Nikita Thapa; Beom Joon Kim; Jung Ok Lee; You Na Jang; Yong Joon Chwae; Jaeyoung Kim
Journal:  Mol Med Rep       Date:  2021-11-25       Impact factor: 2.952

6.  Translating a Thin-Film Rehydration Method to Microfluidics for the Preparation of a SARS-CoV-2 DNA Vaccine: When Manufacturing Method Matters.

Authors:  Allegra Peletta; Eakachai Prompetchara; Kittipan Tharakhet; Papatsara Kaewpang; Supranee Buranapraditkun; Nongnaphat Yostrerat; Suwimon Manopwisedjaroen; Arunee Thitithanyanont; Jonathan Avaro; Leonard Krupnik; Antonia Neels; Kiat Ruxrungtham; Chutitorn Ketloy; Gerrit Borchard
Journal:  Pharmaceutics       Date:  2022-07-07       Impact factor: 6.525

7.  Immunogenicity and protective efficacy of a DNA vaccine inducing optimal expression of the SARS-CoV-2 S gene in hACE2 mice.

Authors:  Zhuo-Xin Li; Sheng Feng; He Zhang; Xin-Yu Zhuang; Chao Shang; Shi-Yu Sun; Ji-Cheng Han; Yu-Biao Xie; Jin-Yong Zhang; Wei Wang; Cheng-Hui Li; Guan-Yu Zhao; Peng-Fei Hao; Jun-Xian Ma; Yan Gao; Jia-Qing Zeng; Ming-Yao Tian; Zhuo Ha; Hui-Jun Lu; Ning-Yi Jin
Journal:  Arch Virol       Date:  2022-09-09       Impact factor: 2.685

8.  Immunogenic Properties of the DNA Construct Encoding the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein.

Authors:  M B Borgoyakova; L I Karpenko; A P Rudometov; D V Shanshin; A A Isaeva; V S Nesmeyanova; N V Volkova; S V Belenkaya; D E Murashkin; D N Shcherbakov; E A Volosnikova; E V Starostina; L A Orlova; N V Danilchenko; A V Zaikovskaya; O V Pyankov; A A Ilyichev
Journal:  Mol Biol       Date:  2021-12-17       Impact factor: 1.374

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.